Skip to main content

Muscle Loss and Frailty in Rheumatic Disease

“If exercise could be purchased in a pill, it would be the single most widely prescribed and beneficial medicine in the nation.” —Robert H. Butler, MD, first director of the National Institute on Aging.

ACR 2019 - Report from Day One (Sunday)

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis

IL-17 inhibitors in non-radiographic axial SpA

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Test on New ACR19 Site

Body text

ACR 2018 - Day 4 Report

Highlights from Tuesday and Wednesday day 3  and 4 of the ACR Annual meeting in Chicago, included:

Rheumatology Roundup - Drs. Artie Kavanaugh and Jack Cush

FEAR: A Perception of Fact In Spite of the Fiction

Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve.

Tweets

Dr. Antoni Chan synovialjoints

8 months ago

Results from2 anti-IL-17 agents Secukinumab and Ixekizumab in non-radiographic axial Spondyloarthritis poster #L2 and abstract #2729 is promising as treatment options for patients #ACR19 @RheumNow

Dr. Antoni Chan synovialjoints

8 months ago

The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected safety findings. IXE superior to PBO for improving signs, symptoms, and inflammation on MRI in pts with nr-axSpA abstract #2729 #ACR19 @RheumNow

Dr. Antoni Chan synovialjoints

8 months ago

PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs and symptoms of nr-axSpA through Wk 16. The safety profile of SEC was consistent with the established safety profile across indications #L2 #ACR19 @RheumNow

Kanika Monga, MD DrKanikaMonga

8 months ago

Abstract #0626 Are there really differences between non-radiographic and radiographic axial spondyloarthritis? Data from the Spanish Atlas #ACR19 @RheumNow https://t.co/hg3U2QjpFp

Maeve Gamble MaeveGamble

8 months ago

Abstr#2273: higher placental transfer antiTNFs=ADA,IFX,GOL. Less transfer=CTZ,ETN. No ⬆️ in infxns in offspring, even with 3rd tri exposure. Potential trend for ⬆️ in serious infxns (>/=1 hosp adm 1st yr of life) with high placental transfer antiTNFs, not sig.

Jonathan Hausmann MD hausmannMD

8 months ago

Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A ASAS40: a composite measure including patient global, pain, function, and inflammation In patients with nr-AxSpA, secukinumab improved ASAS40 through week 52, compared to placebo Dr.

Philip Robinson philipcrobinson

8 months ago

Video from @gensler_MD on AS and nr-axSpA studies presented at #ACR19 @rheumnow https://t.co/fcn9zCxouU via @YouTube

Dr. Antoni Chan synovialjoints

8 months ago

5-year effectiveness of TNFi in patients with early axSpA shown, male gender, HLAB27 positive and presence of at least one objective sign of inflammation or structural damage are more frequently associated with effectiveness #2776 by Molto #ACR19 @RheumNow

Philip Robinson philipcrobinson

8 months ago

@_connectedcare @RheumNow @ACRheum My pearls (so far) 1. Use vitamin A to reduce SEs w MTX 2. Try doxycycline for refractory calcinosis in scleroderma 3. Use MTX with pegloticase to reduce infusion reactions 4. Anti-IL17 has activity in nr-axSpA 5.

Maeve Gamble MaeveGamble

8 months ago

Abstr#2729: 303 pts randomized. More pts achieved ASAS40 at Wk 16: IXE Q2W (40%), IXE Q4W (35%) vs PBO (19%, p< 0.01) and at Wk 52: IXE Q2W (31%), IXE Q4W (30%) vs PBO (13%, p< 0.01). Blocking IL-17A is a potential treatment option for patients with nr-axSpA. #ACR19 @RheumNow

×